Q&A: BioMarin commercial chief Jeff Ajer gears up for biggest drug launch to date — with another waiting in the wings
Is BioMarin’s chief commercial officer ready to get off the company’s rollercoaster ride of the past few years? Not necessarily. As CCO Jeff Ajer says it’s expected at BioMarin that “drug development does not go in a straight line.”
Although right now BioMarin’s line seems to be a straight line heading up. Last week it posted positive data for its hemophilia A gene therapy Roctavian, bouncing back after a surprise FDA CRL in 2020 that requested more data. It has already filed for Roctavian’s approval in Europe and plans to submit to the FDA again in the second quarter. Meanwhile, in November, it nabbed an FDA nod for Voxzogo, the first approved drug to treat children with achondroplasia, the most common form of dwarfism, following on a summer approval in Europe.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.